Revolutionizing COPD Treatment Through Regenerative Medicine

At MimeCure, we are committed to revolutionizing the quality of life for thousands of patients suffering from Chronic Obstructive Pulmonary Disease (COPD). Despite the significant need, there is currently no effective therapy available for these patients.

Introducing MC002: A Breakthrough in COPD Therapy

Our breakthrough compound, MC002, is an active fragment of the protein Mimecan. It is the first therapy designed to promote the regeneration of alveolar epithelial cells and lung tissue, offering new hope for those affected by COPD. By enabling alveolar regeneration, MC002 has the potential to alter the course of this debilitating disease, dramatically improving patient outcomes and reducing the societal and economic burden of COPD.